Please use this identifier to cite or link to this item: https://hdl.handle.net/1959.11/23174
Title: Click Chemistry in Carbohydrate Based Drug Development and Glycobiology
Contributor(s): Wilkinson, Brendan  (author)orcid ; Bornaghi, Laurent (author); Poulsen, Sally-Ann (author); Houston, Todd (author)
Publication Date: 2007
Handle Link: https://hdl.handle.net/1959.11/23174
Abstract: The 1,3-dipolar cycloaddition reaction (1,3-DCR) of a 1,3-dipole to a dipolarophile for the synthesis of heterocycles is a ubiquitous transformation in synthetic organic chemistry. Recently, the Sharpless and Melda! groups have reported the dramatic rate enhancement (up to 107 times) and improved regioselectivity of the Huisgen 1,3-DCR of an organic azide to a terminal acetylene to afford, specifically a l ,4-disubstituted-1,2,3- triazole in the presence of a Cu1 catalyst. This Cu1 catalysed 1,3-DCR has successfully fulfilled the requirements of "click chemistry" as prescribed by Sharpless and within the past few years has become a premier component of the click chemistry paradigm. Click chemistry has proven to be of remarkable utility and broad scope, not only in organic synthesis, but in chemical biology and drug discovery. Click chemistry is highly modular and simplifies difficult syntheses. The biocompatibility of the reaction, tolerance towards a broad range of pH and relative inertness of acetylenes and azides within highly functionalised biological milieus has allowed click chemistry to become a viable bioconjugation strategy both for labelling biomolecules and for in situ lead discovery applications. More recently, click chemistry has emerged as a powerful conjugation strategy for the preparation of structurally diverse neoglycoconjugates of biomedical interest. This chapter aims to highlight recent developments appearing within the literature concerning the use of click chemistry in carbohydrate based drug discovery and glycobiology. Topics range from small molecule probes and drug leads, multivalent neoglycoconjugates acting as Iectin inhibitors and potential vaccines, to bioconjugation strategies for labelling of engineered cell surface glycans. The chapter aims to be comprehensive with commentary on future perspective.
Publication Type: Book Chapter
Source of Publication: Drug Design Research Perspectives, p. 57-102
Publisher: Nova Science Publishers, Inc
Place of Publication: New York, United States of America
ISBN: 1600218237
9781600218231
Fields of Research (FoR) 2008: 030503 Organic Chemical Synthesis
030401 Biologically Active Molecules
030405 Molecular Medicine
Fields of Research (FoR) 2020: 340401 Biologically active molecules
340503 Organic chemical synthesis
340406 Molecular medicine
Socio-Economic Objective (SEO) 2008: 970103 Expanding Knowledge in the Chemical Sciences
970106 Expanding Knowledge in the Biological Sciences
Socio-Economic Objective (SEO) 2020: 280105 Expanding knowledge in the chemical sciences
280102 Expanding knowledge in the biological sciences
HERDC Category Description: B1 Chapter in a Scholarly Book
Publisher/associated links: https://nla.gov.au/anbd.bib-an41735495
Editor: Editor(s): Stanley P Kaplan
Appears in Collections:Book Chapter
School of Science and Technology

Files in This Item:
3 files
File Description SizeFormat 
Show full item record

Page view(s)

1,920
checked on Mar 24, 2024
Google Media

Google ScholarTM

Check


Items in Research UNE are protected by copyright, with all rights reserved, unless otherwise indicated.